New “Semisynthetic” Anti-Malarial Drug is Unneeded and Sets Dangerous Precedent While Threatening Farmer Livelihoods
By Press Release,
SynBioWatch
| 04. 15. 2013
SynBioWatch Press Release:
For Immediate Release
April 15, 2013
Contact: Lisa Archer, Gopal Dayaneni, or Tina Stevens, , (510) 982-1285, info@SynBioWatch.org
Pharmaceutical giant Sanofi Aventis and Amyris Biotech founder Jay Keasling have announced that they intend to replace the entire world supply of the World Health Organization’s preferred anti-malarial treatment derived from botanical artemisinin with a semisynthetic product which employs synthetic biology, a controversial, unregulated biotechnology.
Speaking at a conference in Cambridge, UK, Keasling said, “Moves are afoot to replace the entire world supply” of artemisinin, which is currently produced by thousands of farmers in Kenya, Tanzania, Madagascar, Mozambique, India, Vietnam and China who cultivate sweet wormwood, the natural source of artemisinin. The statement was confirmed in a release by Sanofi outlining their plan to begin large-scale production.
Currently unregulated, synthetic biology is an extreme form of genetic engineering that involves replacing the genetic material of microbes with entirely artificial human designed gene sequences, resulting in new organisms that are then ‘put to work’ as microbial ‘factories.’
The news raised a host of red flags among civil society organizations concerned...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Emile Torres, Jacobin | 11.15.2025
Watching tech moguls throw caution to the wind in the AI arms race or equivocate on whether humanity ought to continue, it’s natural to wonder whether they care about human lives.
The earnest, in-depth answer to this question is just...
By Emily Mullin, Wired | 10.30.2025
In 2018, Chinese scientist He Jiankui shocked the world when he revealed that he had created the first gene-edited babies. Using Crispr, he tweaked the genes of three human embryos in an attempt to make them immune to HIV and...
